Dosing Guidlines for Adults
Drug Detail for Adult Drugs
Atovaquone
Antimicrobial Agents
Antiparasitic Antibiotics
- General Toxicity Notes
-
- Excreted Unchanged %
- <1
- Half-Life (NormalESRD) hours
- 55-77/No data
- Plasma Protein Binding %
- 99
- Volume of Distribution L/kg
- No data
- Dose for Normal Renal Function
- 750-1500 mg q12h(susp)-q24h
- Second Dose
-
- Adjustment for Renal Failure Method
-
- Adjustment for Renal Failure GFR, mL/min >50 [Recommended Level]
- No data: 100%[D]
- Adjustment for Renal Failure GFR, mL/min 10-50 [Recommended Level]
- No data: 100%[D]
- Adjustment for Renal Failure GFR, mL/min <10 [Recommended Level]
- No data: 100%[D]
- Supplement for Dialysis [Recommendation Level]: IHD
- IHD: No data: None
- Supplement for Dialysis [Recommendation Level]: PD
- PD: No data: None
- Supplement for Dialysis [Recommendation Level]: CRRT
- CRRT: Dose for GFR 30-50, [D]
- References
- Dixon R, Pozniak AL, Watt HM, Rolan P, Posner J. Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients. Antimicrob Agents Chemother. 1996; 40: 556-60. [PMID: 8851570] / Hughes WT, Kennedy W, Shenep JL, Flynn PM, Hetherington SV, Fullen G, et al. Safety and pharmacokinetics of 566C80, a hydroxynaphthoquinone with anti-Pneumocystis carinii activity: a phase I study in human immunodeficiency virus (HIV)-infected men. J Infect Dis. 1991; 163: 843-8. [PMID: 2010637]
- Toxicity Notes
-